美国Kendle International Inc. 
Kendle International Inc. (Nasdaq: KNDL) 是全球领先的临床研究机构，为全球生物制药行业提供全面的初期到后期临床开发服务。该公司所注重的创新型解决方案能够为客户缩短循环周期并加快增强生命的药物推向市场，让全球患者受益。作为发展最快的全球性 I-IV 期服务供应商之一，该公司提供覆盖99个国家和地区的业务经验，还有业界领先的患者招募途径和保留能力以及广泛的治疗专长，可以解决其客户面临的临床开发难题。
Kendle 被《财富》(FORTUNE) 杂志评为2008年美国发展最快的百强公司之一。该公司还在美国调查点的 CenterWatch 2007 调查中被列为“Top CRO to Work With”（最佳共事临床研究机构），在欧洲调查点的2008年调查中被列为“Top CROs in Europe”（欧洲最佳临床研究机构）之一。

Kendle is a leading global clinical research organization providing the full range of early– to late–stage clinical development services for the world's biopharmaceutical industry. Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery of life-enhancing drugs to market for the benefit of patients worldwide.

As one of the fastest-growing global providers of Phase I-IV services we offer experience spanning more than 100 countries, along with industry-leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers' clinical development challenges. Kendle was recognized by FORTUNE magazine as one of the 100 fastest-growing companies in the United States for 2008 and was named "Top CRO to Work With" in the CenterWatch 2007 biannual survey of U.S. investigative sites.

For nearly three decades, Kendle has served customers, both large and small, and with a diversity of compounds, which means that our expertise spans every major therapeutic area. We have focused our therapeutic offerings on market needs and are already aligned with the top areas expected to represent more than 70 percent of worldwide drug sales through 2013: oncology/hematology, antibiotics/antivirals, cardiology, arthritis/inflammation, CNS, respiratory and diabetes/metabolism.1

Our vision
To be the best-in-class provider of clinical development services to the biopharmaceutical industry through broad therapeutic and geographic expertise.

Our corporate imperatives

Drive growth and profitability
Focus on our customer and build our brand
Maximize quality and increase capability
Develop talent and reward performance